Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 277

1.

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.

Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N.

Pharmacoeconomics. 2012 Nov 1;30(11):991-1004. doi: 10.2165/11597160-000000000-00000. Review.

PMID:
22950547
2.

Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.

Norman G, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, Clifton I, Paton J, Woolacott N, McKenna C.

Health Technol Assess. 2013 Nov;17(52):1-342. doi: 10.3310/hta17520. Review.

3.

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years.

Walker S, Burch J, McKenna C, Wright K, Griffin S, Woolacott N.

Health Technol Assess. 2011 May;15 Suppl 1:13-21. doi: 10.3310/hta15suppl1/02. Review.

4.

Omalizumab for the treatment of severe persistent allergic asthma.

Jones J, Shepherd J, Hartwell D, Harris P, Cooper K, Takeda A, Davidson P.

Health Technol Assess. 2009 Sep;13 Suppl 2:31-9. doi: 10.3310/hta13suppl2/05. Review.

5.

Omalizumab for asthma in adults and children.

Normansell R, Walker S, Milan SJ, Walters EH, Nair P.

Cochrane Database Syst Rev. 2014 Jan 13;(1):CD003559. doi: 10.1002/14651858.CD003559.pub4. Review.

PMID:
24414989
6.

Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.

Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce IN, Sculpher M, Woolacott N.

Pharmacoeconomics. 2012 Apr;30(4):257-70. doi: 10.2165/11595920-000000000-00000. Review.

PMID:
22283690
7.

Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.

Faria R, McKenna C, Palmer S.

Value Health. 2014 Dec;17(8):772-82. doi: 10.1016/j.jval.2014.07.009. Epub 2014 Oct 11.

8.

Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective.

Levy AN, García A Ruiz AJ, García-Agua Soler N, Sanjuan MV.

J Asthma. 2015 Mar;52(2):205-10. doi: 10.3109/02770903.2014.941474. Epub 2014 Nov 24.

PMID:
24995661
9.

The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.

Dewilde S, Turk F, Tambour M, Sandström T.

Curr Med Res Opin. 2006 Sep;22(9):1765-76.

PMID:
16968580
10.

Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Bermejo I, Stevenson M, Cooper K, Harnan S, Hamilton J, Clowes M, Carroll C, Harrison T, Saha S.

Pharmacoeconomics. 2018 Feb;36(2):131-144. doi: 10.1007/s40273-017-0571-8. Review.

PMID:
28933002
11.

Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands.

van Nooten F, Stern S, Braunstahl GJ, Thompson C, Groot M, Brown RE.

J Med Econ. 2013;16(3):342-8. doi: 10.3111/13696998.2012.756398. Epub 2012 Dec 18.

PMID:
23216016
12.
13.

Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal.

Rodgers M, Griffin S, Paulden M, Slack R, Duffy S, Ingram JR, Woolacott N, Sculpher M.

Pharmacoeconomics. 2010;28(5):351-62. doi: 10.2165/11532160-000000000-00000. Review.

PMID:
20131924
14.

Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.

Wade R, Rose M, Neilson AR, Stirk L, Rodriguez-Lopez R, Bowen D, Craig D, Woolacott N.

Pharmacoeconomics. 2013 Oct;31(10):841-52. doi: 10.1007/s40273-013-0083-0. Review.

PMID:
23996108
15.

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W.

Ann Intern Med. 2011 May 3;154(9):573-82. doi: 10.7326/0003-4819-154-9-201105030-00002.

PMID:
21536936
16.

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.

Bagust A, Greenhalgh J, Boland A, Fleeman N, McLeod C, Dickson R, Dundar Y, Proudlove C, Shaw R.

Pharmacoeconomics. 2010;28(6):439-48. doi: 10.2165/11532220-000000000-00000. Review.

PMID:
20465313
17.

The role of omalizumab in the treatment of severe allergic asthma.

Chapman KR, Cartier A, Hébert J, McIvor RA, Schellenberg RR.

Can Respir J. 2006 Jul-Aug;13 Suppl B:1B-9B. Review.

18.

Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).

Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM; QUALITX Study Investigators.

J Asthma. 2012 Apr;49(3):288-93. doi: 10.3109/02770903.2012.660297. Epub 2012 Feb 23.

PMID:
22356355
19.

Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.

Zafari Z, Sadatsafavi M, Marra CA, Chen W, FitzGerald JM.

PLoS One. 2016 Jan 11;11(1):e0146003. doi: 10.1371/journal.pone.0146003. eCollection 2016.

20.

A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.

Dal Negro RW, Tognella S, Pradelli L.

J Asthma. 2012 Oct;49(8):843-8. doi: 10.3109/02770903.2012.717659. Epub 2012 Sep 7.

PMID:
22954018

Supplemental Content

Support Center